Edwards Lifesciences Corporation
EW
$76.04
$0.911.21%
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 4.24% | 697.82% | 19.28% | 3.35% | -7.15% |
| Total Depreciation and Amortization | 16.08% | -6.50% | 9.70% | 9.38% | 3.67% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -71.80% | -181,000.00% | 87.37% | 808.33% | 18.46% |
| Change in Net Operating Assets | -114.30% | 5,703.28% | 89.37% | -624.20% | -154.53% |
| Cash from Operations | -193.34% | -14.51% | 1,005.65% | -117.03% | -51.70% |
| Capital Expenditure | 43.60% | 6.15% | -78.29% | -6.18% | -28.16% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -748.26% | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -505.50% | -384.27% | 77.98% | -36.81% | -65.53% |
| Cash from Investing | -4,190.07% | 2,935.62% | 77.78% | 12,520.00% | -85.11% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -13.86% | 1.47% | -10.69% | 48.21% | 20.73% |
| Repurchase of Common Stock | 99.98% | -473.97% | -2,008.00% | 99.92% | 48.22% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -95.00% | -251.72% | 700.00% | -125.00% | 566.67% |
| Cash from Financing | 106.92% | -581.58% | -285.41% | 129.86% | 50.72% |
| Foreign Exchange rate Adjustments | 1,600.00% | -659.78% | 93.42% | 330.95% | 81.32% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -134.90% | 452.76% | 150.79% | -21.97% | 44.50% |